 "AstraZeneca sells antacid brand Neksium to Pfizer India for Rs 75 cr")
AstraZeneca AB, Sweden, has sold its antacid brand Neksium to Pfizer Ltd, which also owns Gelusil brand, for Rs 75 crore. The transaction is subject to completion of requisite clearances.
Launched in India in 2006, Neksium is one the leading brands in the anti-peptic ulcerant space. Neksium, with the active ingredient esomeprazole belongs to a class of pharmaceutical preparations called proton pump inhibitors (PPI), which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the acid peptic disorders (APD) spectrum.
“The Neksium acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the gastrointestinal (GI) therapy area,” commented S Sridhar, managing director, Pfizer Ltd.
With brands such as Gelusil & Mucaine, Pfizer Ltd has been providing effective solutions in the antacid space for over 30 years. “The company is uniquely well placed to grow the Neksium brand further through its existing reach, coverage and equity in the GI therapy area,” added Pfizer in a press release.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%